Abstract 2250
Background
Induction chemotherapy (ICT) followed by bioradiotherapy (BRT) is a validated conservative approach for fit LA-HNSCC patients (pts). However, in pts unfit for cisplatin-based chemotherapy, this treatment strategy remains a challenge. Paclitaxel in combination with anti-EGFR therapy is active and well-tolerated in the recurrent/metastatic setting. This study aims to evaluate this regimen as ICT followed by BRT.
Methods
A retrospective single institution analysis (2010-2016) of LA-HNSCC pts unfit for cisplatin-based chemotherapy (≥70 years-old and/or significant comorbidity) was performed. Pts were treated with paclitaxel plus anti-EGFR monoclonal antibody up to 9 weeks followed by radical BRT (IMRT with concurrent anti-EGFR therapy). Overall survival (OS) and progression free survival (PFS) were estimated by Kaplan-Meier method.
Results
A total of 44 pts were evaluated: median age 72 years-old (50-83), male 42; tumor location, pts (%): larynx 14 (32), oropharynx 10 (23) (HPV+ 0), hypopharynx 9 (21), oral cavity 7 (16), cervical unknown primary 4 (9); 7thed TNM stage, pts (%): EIII 11 (25), EIVa 19 (43) and EIVb 14 (32). ECOG status 0/1/2: 1/38/5 pts. Response rate to ICT: 32 pts (73%); 5 complete responses (CR) and 27 partial responses (PR). During ICT 5 pts (11%) presented grade 3/4 adverse events, and 1 patient (2%) died due to febrile neutropenia. 37 pts (84%) continued with radical BRT: 20 pts (45%) achieved CR, and 6 of them recurred. Median follow-up: 13.5 (1-52) months. For the whole cohort, median OS and PFS were 15.6 (95% CI 4.7-26.6) and 10.4 (95% CI 7.0-13.7) months, respectively. For the 35 pts who completed ≥6 weeks of ICT, median OS and PFS were 22.2 (95% IC 7.2-37.2) and 15.6 (95% IC 8.4-22.9) months, respectively. Larynx pts showed better outcome in comparison with other locations: median OS not reached (NR) vs 10.7 (p = 0.003) and median PFS NR vs 0 (p = 0.001); 9 pts (64%) preserved a functioning larynx and were alive by the time of the analysis.
Conclusions
Paclitaxel plus anti-EGFR therapy was well-tolerated and might be an effective ICT regimen for LA-HNSCC pts unfit for cisplatin. In our cohort, larynx pts obtained the greatest benefit from this regimen.
Clinical trial identification
Legal entity responsible for the study
Institut Catala de Oncologia.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4162 - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
Presenter: Anu Moilanen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3747 - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
Presenter: Roman Dubianski
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4688 - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.
Presenter: Pietro Paolo Vitiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
498 - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Presenter: Xiao Fu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3731 - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1215 - Cisplatin in NIPEC or HIPEC?
Presenter: Ivan Alvovsky
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2738 - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
Presenter: MARIKO HIRAI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2190 - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
Presenter: Priya Sriskandarajah
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor
Presenter: Davide Ciardiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
624 - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
Presenter: Hugo Arasanz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract